# DESCRIPTION

## ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

- acknowledge government support

## BACKGROUND

- introduce pattern recognition receptors
- describe PRR-mediated signaling
- discuss IFN synthesis and secretion
- describe IRF3 phosphorylation
- introduce STING as PRR and adaptor molecule
- discuss IFN stimulation as antiviral strategy
- introduce TLR agonists
- discuss RIG-I/MDA5/IPS-1 stimulation
- introduce CMA and DMXAA as STING activators
- discuss limitations of CMA and DMXAA
- introduce Alphavirus genus
- describe CHIKV and VEEV outbreaks
- discuss lack of FDA-approved antiviral drugs and vaccines
- introduce type I IFN sensitivity of Alphaviruses
- discuss IRF3/IFN activation via IPS-1 pathway
- introduce pharmacologic activation of IRF3/IFN via STING
- discuss potential therapeutic application
- introduce CRISPR/Cas9-mediated gene editing
- discuss in vivo stimulation of STING pathway

## SUMMARY

- introduce STING as PRR and adaptor protein
- describe STING-dependent signaling
- introduce small molecules as STING activators
- discuss antiviral and antitumor immunity
- introduce first synthetic small molecule STING activator
- discuss prevention of Alphavirus replication
- introduce in vivo stimulation of STING pathway
- discuss potential therapeutic application
- introduce methods of identifying STING agonists

## DETAILED DESCRIPTION

### Terms

- define technical terms
- explain singular and plural referents
- define "or" and "and"
- explain approximate values for base sizes and molecular weights
- define "include" and "comprise"
- explain "consisting essentially of" and "consisting of"
- define agonist
- define alkyl
- define aryl
- define bioluminescent proteins or photoproteins
- define contacting
- define control
- define derivative
- define effective amount
- define fluorescent protein
- define heterocycle
- define label
- explain protein tags
- define operably linked
- define polynucleotide
- define polypeptide
- define promoter
- define recombinant
- define subject
- define test compound
- define treatment
- explain prophylactic and therapeutic treatments
- summarize terms
- conclude terms

### Compounds:

- disclose compounds of formulas

### Pharmaceutical Compositions

- formulate pharmaceutical compositions
- combine compounds with pharmaceutically acceptable carriers
- administer by mucosal administration modes
- administer by non-mucosal routes
- formulate with various additives
- adjust tonicity of formulation
- disperse compound in pharmaceutically acceptable carrier
- select carrier from wide range of compounds
- use biodegradable polymer as carrier
- employ synthetic fatty acid esters as carriers
- combine compound with carrier according to various methods
- release compound by diffusion or disintegration
- disperse compound in microcapsules or nanoparticles
- formulate as solution, microemulsion, or ordered structure
- maintain proper fluidity for solutions
- include isotonic agents in composition
- prolong absorption with agents that delay absorption
- administer in time release formulation

### Treatment

- treat alphavirus infection with compositions
- administer by various routes
- administer for prophylactic or therapeutic purposes
- provide treatments in single bolus delivery or repeated administration
- determine therapeutically effective dosage
- reduce or inhibit symptoms associated with disease
- adjust dosage regimens for optimum response
- determine effective amount based on animal model studies
- guide administration protocols by reducing disease symptoms
- calculate concentration and dose for therapeutically effective amount

## EXAMPLES

### Example 1 Identification of a Novel IFN/IRF3-Inducing Molecule by High Throughput In Vitro Screening

- describe high-throughput in vitro screening methodology
- identify G10 molecule

### Example 2—G10 Induces IFN/IRF3- but not NF-κB-Dependent Transcription in Human Fibroblasts

- confirm G10-mediated induction of IFN/IRF3-dependent LUC
- examine induction of IRF3-dependent mRNA by G10
- show lack of G10-mediated NF-κB-dependent transcription

### Example 3—G10 Elicits Antiviral Activity Against New and Old World Alphaviruses

- examine G10-mediated antiviral activity against various viruses
- show potent inhibition of CHIKV and VEEV replication by G10
- compare antiviral activity of G10 against different viruses
- discuss implications of G10's antiviral activity

### Example 4—IRF3 is Essential to G10-Induced Transcription and Anti-Alphaviral Activity

- generate IRF3- and STAT1-deficient cells
- validate absence of IRF3 and STAT1 proteins
- examine G10-induced LUC expression in IRF3- and STAT1-deficient cells
- show IRF3 phosphorylation in response to G10
- examine anti-Alphaviral activity of G10 in IRF3-deficient cells
- discuss requirement of IRF3 for G10's anti-Alphaviral activity

### Example 5—G10-Mediated IRF3 Activation and Anti-Alphaviral Activity Occur Independently of IPS-1/MAVS-Dependent Signaling

- generate IPS-1-deficient cells
- validate absence of IPS-1 protein
- examine G10-induced IRF3 phosphorylation in IPS-1-deficient cells
- show anti-Alphaviral activity of G10 in IPS-1-deficient cells

### Example 6—STING is Required for G10-Mediated IRF3 Activation, Gene Expression, and Anti-Alphaviral Activity

- generate STING-deficient cells
- validate absence of STING protein
- examine G10-induced IRF3 phosphorylation in STING-deficient cells
- show lack of G10-induced LUC expression in STING-deficient cells
- examine G10-induced transcription of endogenous genes in STING-deficient cells
- show anti-Alphaviral activity of G10 in STING-deficient cells
- discuss requirement of STING for G10's anti-Alphaviral activity
- examine thermal stability of STING-CTD with G10
- discuss lack of direct binding between G10 and STING-CTD
- discuss potential engagement of upstream PRRs by G10
- discuss implications of G10's mechanism of action

### Example 7—G10 Induces STING-Dependent Synthesis and Secretion of Bioactive Interferon

- examine G10-induced transcription of IFNβ and IFNλ1 mRNAs
- show induction of IFNα/β-dependent genes by G10
- discuss secretion of IFN in response to G10
- examine secreted interferon using a cell-based reporter assay
- show IFN secretion by wild type and IPS-1-deficient cells
- show lack of IFN secretion by STING-deficient cells
- discuss implications of G10's induction of IFN secretion

### Example 8—STAT1 is Required for G10-Mediated Anti-Alphaviral Activity and ISG Expression

- demonstrate G10-mediated anti-Alphaviral activity
- examine replication of viruses in STAT1-deleted cells
- show IFN-induced antiviral effects in absence of STAT1
- investigate ISG expression in STAT1-deficient cells

### Example 9—G10 Triggers IRF3-Dependent Activity with Less Potency than 2′3′-cGAMP

- compare G10 and 2′3′-cGAMP IRF3 phosphorylation kinetics
- examine IRF3-dependent gene induction in response to G10 and 2′3′-cGAMP
- illustrate phosphorylation of IRF3 S386
- show transcriptional induction of IRF3- and IFN-dependent genes
- compare dose-dependent induction of IRF3-dependent genes
- illustrate transcription of IFNβ
- describe limitations of 2′3′-cGAMP transfection
- summarize G10-mediated innate immune reactivity
- introduce Example 10
- introduce primary human cells
- examine IRF3-, IFN-, and NF-κB-dependent gene expression
- illustrate G10-induced expression of IFIT1, IFIT2, IFNβ, ISG15, OAS, and Viperin
- introduce Example 11
- introduce STING agonism
- inhibit CHIKV replication in vivo
- administer DMSO or DMXAA to mice
- examine serum viral titers
- illustrate undetectable virus in serum
- examine viral titers with post-infection treatment
- illustrate diminished viral titers
- discuss antiviral efficacy
- discuss recurrent STING activation
- introduce pharmacologic activation of STING-dependent signaling
- discuss therapeutic strategy
- introduce G10
- trigger IRF3/IFN-dependent responses
- block replication of CHIKV, VEEV, and SINV
- identify cellular targets
- use reverse genetics approach
- identify STING protein
- discuss G10's biological activity
- discuss IRF3-dependent gene expression
- discuss type I and III IFN synthesis
- discuss antiviral activity
- discuss IPS-1 deletion
- discuss IPS-1 interaction with STING
- discuss STING-dependent function
- discuss G10's inability to induce IRF3-dependent transcription
- discuss alternative STING-dependent PRRs
- compare G10 and 2′3′-cGAMP dose dependence
- discuss differences in stimulatory potency
- discuss physico-chemical properties
- introduce cell lines and culture conditions
- describe virus strains and infection methods
- outline cell viability assay
- describe immunoblotting protocol
- outline RNA isolation and RT-PCR
- describe lentivector transduction and CRISPR/Cas9 genome editing
- outline luciferase reporter assays
- describe STING protein purification and thermal shift assays
- outline in vivo administration of DMXAA and viral infection
- describe synthesis of G10 and analogs
- detail human foreskin fibroblasts cell line
- describe Vero, BHK-21, and C6/36 cell lines
- outline RAW264.7 cell line and lentivector transduction
- describe THP1-ISG Lucia cell line and differentiation
- outline human peripheral blood mononuclear cells and maintenance
- describe human umbilical microvascular endothelial cells and maintenance
- detail Sendai virus and cytomegalovirus infection
- outline West Nile Virus, Vaccinia Virus, Sindbis virus, and Venezeulan encephalitis virus infection
- describe CHIKV infection and propagation
- outline infectious virus quantification
- describe cell viability examination
- detail immunoblotting procedure
- outline RNA isolation and cDNA synthesis
- describe qPCR and primer/probe sets
- detail lentivector-mediated CRISPR/Cas9 genome editing

